Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant Considers Alternatives As Court Enjoins Paclitaxel DELIVER Data

This article was originally published in The Gray Sheet

Executive Summary

Guidant is exploring a supply arrangement that would be consistent with Cook, Inc.'s original licensing agreement with Angiotech Pharmaceuticals in moving forward with a paclitaxel-eluting stent platform

You may also be interested in...



TAXUS II Data Show Paclitaxel Effective In Two Dose-Release Modalities

Boston Scientific's plans to change the design of its upcoming TAXUS V study in the U.S. suggest that the company is leaning toward the slow-release formulation of paclitaxel for its drug-eluting stent development program

Guidant’s $3 Bil. Cook Purchase Hinges On Ownership Of Subsidiary, Data

Guidant's $3 bil. purchase of Cook Group does not represent a "change of ownership" under the terms of a 1997 licensing agreement between subsidiary Cook, Inc., Angiotech Pharmaceuticals and Boston Scientific, Guidant asserts

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel